Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|September 13, 2007

FDA Approves Somatuline Depot for Acromegaly

On August 31, 2007, the US Food and Drug Administration (FDA) approved Somatuline depot (lanreotide) injection 60, 90, and 120 mg for marketing in the United States.

On August 31, 2007, the US Food and Drug Administration (FDA) approved Somatuline depot (lanreotide acetate injection) 60, 90, and 120 mg for marketing in the United States. Somatuline depot, manufactured by Tercica, Inc. (Brisbane, CA, www.tercica.com), is indicated for the long-term treatment of acromegaly in patients who have had an inadequate response to surgery or radiotherapy, or for whom surgery or radiotherapy is not an option. Somatuline depot will be available in a pre-filled syringe eliminating the need for reconstitution. Somatuline depot is expected to launch in the United States in the fourth quarter 2007.


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.